ReleaseWire

Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H2 2014', provides an overview of the Urinary Incontinence's therapeutic pipeline.

GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Global Markets Direct's, 'Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Squamous Cell Carcinoma's therapeutic pipeline.

The Global Pharmaceutical Market Benchmark Report applies GlobalData's proprietary ranking methodology to compare the competitive positions of 30 leading drug companies on 25 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure, and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

Global Markets Direct's, 'FibroGen, Inc. - Product Pipeline Review - 2014', provides an overview of the FibroGen, Inc.'s pharmaceutical research and development focus.

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Global Markets Direct's, 'Sage Therapeutics - Product Pipeline Review - 2014', provides an overview of the Sage Therapeutics's pharmaceutical research and development focus.

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H2 2014', provides an overview of the Male Hypogonadism's therapeutic pipeline.

Global Markets Direct's, 'AnaptysBio, Inc. - Product Pipeline Review - 2014', provides an overview of the AnaptysBio, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Aspergillosis - Pipeline Review, H2 2014', provides an overview of the Aspergillosis's therapeutic pipeline.

Global Markets Direct's, 'Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Peregrine Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Degenerative Osteoarthritis Global Clinical Trials Review, H2, 2014" provides data on the Degenerative Osteoarthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Degenerative Osteoarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Degenerative Osteoarthritis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Dr. Falk Pharma GmbH - Product Pipeline Review - 2014', provides an overview of the Dr. Falk Pharma GmbH's pharmaceutical research and development focus.

Global Markets Direct's, 'Alcoholic Hepatitis - Pipeline Review, H2 2014', provides an overview of the Alcoholic Hepatitis's therapeutic pipeline.

GlobalData's clinical trial report, "Acute Lung Injury Global Clinical Trials Review, H2, 2014" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H2 2014', provides an overview of the H3N2 Infection's therapeutic pipeline.

Global Markets Direct's, 'Plantacor, Inc. - Product Pipeline Review - 2014', provides an overview of the Plantacor, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Pemphigus Global Clinical Trials Review, H2, 2014" provides data on the Pemphigus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pemphigus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pemphigus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H2 2014', provides an overview of the Epidermolysis Bullosa's therapeutic pipeline.

Global Markets Direct's, 'Wockhardt Limited - Product Pipeline Review - 2014', provides an overview of the Wockhardt Limited's pharmaceutical research and development focus.

GBI Research, the leading business intelligence provider, has released its latest research, "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries", which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of the pipeline, clinical trial failure rate and deal analysis for MDD. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts. In 2013, the value of the MDD therapeutics market in major developed countries amounted to an estimated $8.7 billion. The market is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.1% between 2013 and 2020 to reach $8.1 billion. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period.

Global Markets Direct's, 'Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Neuropathic Pain's therapeutic pipeline.

Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H2 2014', provides an overview of the Smoking Cessation's therapeutic pipeline.

Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.

Global Markets Direct's, 'ImmunoBiology Ltd. - Product Pipeline Review - 2014', provides an overview of the ImmunoBiology Ltd.'s pharmaceutical research and development focus.